Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Fulgent Genetics, Inc. (FLGT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/04/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/04/2023 8-K Investor presentation, Quarterly results
Docs: "June 30, December 31, 2023 2022 ASSETS: Cash and cash equivalents $ 58,348 $ 79,506 Investments in marketable securities 788,466 773,377 Accounts receivable, net 34,809 52,749 Property, plant, and equipment, net 87,556 81,353 Other assets 385,398 399,068 Total assets $ 1,354,577 $ 1,386,053 LIABILITIES & EQUITY: Accounts payable, accrued liabilities and other liabilities $ 91,251 $ 116,178 Total stockholders’ equity 1,263,326 1,269,875 Total liabilities & equity $ 1,354,577 $ 1,386,053 FULGENT GENETICS, INC. Condensed Consolidated Statement of Operations Data Three and Six Months Ended June 30, 2023 and 2022 Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue $ 67,853 $ 125,341 $ 134,021 $ 445,609 Cost of revenue 47,281 60,065 94,638 137,790 Gross profit 20,5...",
"2018 2019 2020 2021 2022 2017 2016"
06/02/2023 144 Form 144 - Report of proposed sale of securities:
06/02/2023 144 Form 144 - Report of proposed sale of securities:
06/02/2023 144 Form 144 - Report of proposed sale of securities:
05/18/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/18/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FULGENT GENETICS, INC."
05/05/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 8-K Investor presentation, Quarterly results
Docs: "March 31, December 31, 2023 2022 ASSETS: Cash and cash equivalents $ 66,172 $ 79,506 Investments in marketable securities 805,146 773,377 Accounts receivable, net 43,549 52,749 Property, plant, and equipment, net 79,083 81,353 Other assets 382,817 399,068 Total assets $ 1,376,767 $ 1,386,053 LIABILITIES & EQUITY: Accounts payable, accrued liabilities and other liabilities $ 107,848 $ 116,178 Total stockholders’ equity 1,268,919 1,269,875 Total liabilities & equity $ 1,376,767 $ 1,386,053 FULGENT GENETICS, INC. Condensed Consolidated Statement of Operations Data Three Months Ended March 31, 2023 and 2022 Three Months Ended March 31, 2023 2022 Revenue $ 66,168 $ 320,268 Cost of revenue 47,357 77,725 Gross profit 18,811 242,543 Operating expenses: Research and development 9,782 5,989 Selling...",
"2018 2019 2020 2021 2022 2017 2016"
03/31/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/31/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/31/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
01/26/2023 SC 13G/A BlackRock Inc. reports a 12% stake in FULGENT GENETICS INC
01/12/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "COMMERCIAL LEASE ADDENDUM This LEASE ADDENDUM II to the Commercial Lease Agreement signed on February 1, 2018 by E&E Plaza LLC and Fulgent Therapeutics LLC . This document modifies the Commercial Lease Agreement as describe below: 1. The Lessor agrees to extend this lease for ONE year, starting on February 1, 2023 and expiring on January 31, 2024. 2. For this one year extension, the Monthly rent shall be adjusted from $23,585.00 to $24,885.00 per month. 3. Lessee remains to be the only occupant of this building. The Lessor will only be responsible for the Property Taxes, Building Insurance, and the Roof of this building. The Lessee is responsible for all of the utilities, upkeep, and maintenance of this building, including the utilities and trash services. 4. All other terms and conditions..."
01/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/23/2022 8-K Quarterly results
11/09/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Quarterly results
Docs: "September 30, December 31, 2022 2021 ASSETS: Cash and cash equivalents $ 168,770 $ 164,894 Investments in marketable securities 749,236 770,652 Accounts receivable, net 104,159 138,912 Property, plant, and equipment, net 81,807 62,287 Other assets 301,810 141,975 Total assets $ 1,405,782 $ 1,278,720 LIABILITIES & EQUITY: Accounts payable, accrued liabilities and other liabilities $ 124,385 $ 112,840 Total stockholders' equity 1,281,397 1,165,880 Total liabilities & equity $ 1,405,782 $ 1,278,720 FULGENT GENETICS, INC. Condensed Consolidated Statement of Income Data Three and Nine Months Ended September 30, 2022 and 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenue $ 105,655 $ 227,868 $ 551,264 $ 740,913 Cost of revenue 59,560 43,466 197,350 ...",
"MANY COMPETITORS DO NOT OFFER",
"2018 2019 2020 2021 2022 2017 2016"
11/04/2022 8-K Quarterly results
09/29/2022 8-K Quarterly results
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/03/2022 8-K Quarterly results
04/26/2022 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits  Interactive Data
Docs: "AGREEMENT AND PLAN OF Merger BY AND AMONG FULGENT THERAPEUTICS LLC, DUCKS ACQUISITION SUB, INC., FULGENT GENETICS, INC., SYMPHONY BUYER, INC., SOLELY IN ITS CAPACITY AS THE Stockholder Representative, Avista Capital Partners IV GP, L.P., AND,"
04/18/2022 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits ...
Docs: "Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results Proposed acquisition will add diagnostic offerings, including hematopathology and anatomic pathology, while also providing a highly complementary nationwide commercial infrastructure to support Fulgent’s rapidly expanding genomic testing footprint Preliminary first quarter revenue results expected to exceed previous guidance provided on February 23, 2022 Fulgent updates full year 2022 core revenue guidance to approximately $175 million including potential revenue contribution from proposed acquisition"
03/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/29/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Fulgent Genetics, Inc. Incentive Compensation Recoupment Policy"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy